How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is expanding its presence in the weight loss and metabolic disease sector through a strategic collaboration with Metsera, Inc., announced in October 2024.

Metsera Inc (NASDAQ: MTSR) has been pushing to the upside since its debut on Nasdaq on January 31. But analysts are convinced ...

A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...

Metsera's lead injectable GLP-1 drug has already demonstrated significant weight loss and tolerability in a Phase 2 obesity trial. Cantor Fitzgerald's analysis suggests that this drug could ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Metsera Inc. MTSR, a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of ...

Metsera’s lead injectable GLP-1 drug has already demonstrated significant weight loss and tolerability in a Phase 2 obesity trial. Cantor Fitzgerald’s analysis suggests that this drug could achieve ...